RT Journal Article
SR Electronic
T1 Associations of comorbidities and medications with COVID-19 outcome: A retrospective analysis of real-world evidence data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.20.20174169
DO 10.1101/2020.08.20.20174169
A1 Abu-Jamous, Basel
A1 Anisimovich, Arseni
A1 Baxter, Janie
A1 Mackillop, Lucy
A1 Vizcaychipi, Marcela P.
A1 McCarthy, Alex
A1 Khan, Rabia T.
YR 2020
UL http://medrxiv.org/content/early/2020/08/23/2020.08.20.20174169.abstract
AB Background Hundreds of thousands of deaths have already been recorded for patients with the severe acute respiratory syndrome coronavirus (SARS-CoV-2; aka COVID-19). Understanding whether there is a relationship between comorbidities and COVID-19 positivity will not only impact clinical decisions, it will also allow an understanding of how better to define the long-term complications in the groups at risk. In turn informing national policy on who may benefit from more stringent social distancing and shielding strategies. Furthermore, understanding the associations between medications and certain outcomes may also further our understanding of indicators of vulnerability in people with COVID-19 and co-morbidities.Methods Electronic healthcare records (EHR) from two London hospitals were analysed between 1st January and 27th May 2020. 5294 patients presented to the hospitals in whom COVID status was formally assessed; 1253 were positive for COVID-19 and 4041 were negative. This dataset was analysed to identify associations between comorbidities and medications, separately and two outcomes: (1) presentation with a COVID-19 positive diagnosis, and (2) inpatient death following COVID-19 positive diagnosis. Medications were analysed in different time windows of prescription to differentiate between short-term and long-term medications. All analyses were done with controls (without co-morbidity) matched for age, sex, and number of admissions, and a robustness approach was conducted to only accept results that consistently appear when the analysis is repeated with different proportions of the data.Results We observed higher COVID-19 positive presentation for patients with hypertension (1.7 [1.3-2.1]) and diabetes (1.6 [1.2-2.1]). We observed higher inpatient COVID-19 mortality for patients with hypertension (odds ratio 2.7 [95% CI 1.9-3.9]), diabetes (2.2 [1.4-3.5]), congestive heart failure (3.1 [1.5-6.4]), and renal disease (2.6 [1.4-5.1]). We also observed an association with reduced COVID-19 mortality for diabetic patients for whom anticoagulants (0.11 [0.03-0.50]), lipid-regulating drugs (0.15 [0.04-0.58]), penicillins (0.20 [0.06-0.63]), or biguanides (0.19 [0.05-0.70]) were administered within 21 days after their positive COVID-19 test with no evidence that they were on them before, and for hypertensive patients for whom anticoagulants (0.08 [0.02-0.35]), antiplatelet drugs (0.10 [0.02-0.59]), lipid-regulating drugs (0.15 [0.05-0.46]), penicillins (0.14 [0.05-0.45]), or angiotensin-converting enzyme inhibitors (ARBs) (0.06 [0.01-0.53]) were administered within 21 days post-COVID-19-positive testing with no evidence that they were on them before. Moreover, long-term antidiabetic drugs were associated with reduced COVID-19 mortality in diabetic patients (0.26 [0.10-0.67]).Conclusions We provided real-world evidence for observed associations between COVID-19 outcomes and a number of comorbidities and medications. These results require further investigation and replication in other data sets.Competing Interest StatementBAJ, AA, JB, LM, and RTK are employees of Sensyne Health plc (part-time in the case of LM) or were employed by Sensyne Health plc over the time period in which they contributed to this study. LM is further funded by The National Institute for Health Research Grant (IS-BRC-1215-20008).Funding StatementThe study was supported by Sensyne Health plc. LM is further funded by The National Institute for Health Research Grant (IS-BRC-1215-20008). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IG management team of Sensyne Health plc and Chelsea & Westminster NHS Foundation Trust under the Strategic Research Agreement (SRA) and relative Data Sharing Agreements (DSAs) signed by the NHS Trust and Sensyne Health plc on 25th July 2018. All analyses were conducted on data with no personal identifying information. Therefore, informed consent was waived by the ethics committee of the Chelsea & Westminster NHS Foundation Trust, which provided ethical approval for the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes_